Pharmaceuticals, Biotechnology and Life Sciences
Akers Biosciences, Inc. a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, has announced that all development specifications have been finalized and production has commenced for its two transformational breath tests designed for the health and wellness industry and consumers.
Merck has announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naïve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection.
Alkermes plcp has announced that the U.S. Food and Drug Administration (FDA) has approved Aristadatm (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
The U.S. Food and Drug Administration ordered on Monday the three manufacturers of duodenoscopes marketed in the U.S. to conduct postmarket surveillance studies to better understand how the devices are reprocessed in real-world settings.
Johnson & Johnson has completed the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion.
The Nobel Assembly at Karolinska Institutet has today decided to award the 2015 Nobel Prize in Physiology or Medicine with one half jointly to William C. Campbell and Satoshi Ōmura for their discoveries concerning a novel therapy against infections caused by roundworm parasites and the other half to Youyou Tu for her discoveries concerning a novel therapy against Malaria.
William C. Campbell and Satoshi Ōmura split Nobel prize in Physiology or Medicine 2015 with Youyou Tu, for discoveries regarding novel therapies for some of the most devastating parasitic diseases.
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
FDA allows Avita to expand its Compassionate Use Investigational Device Exemption (IDE) program for ReCell.
Novartis’s Alcon has received US Food and Drug Administration (FDA) approval for its AcrySof IQ Aspheric IOL with the UltraSert Pre-loaded Delivery System for patients undergoing cataract surgery.